

**DAFTAR PUSTAKA**

- Ahmed, E., Bugti S., Shaikh, A. A., Ejaz, M and Javed, S. 2015. *Isolation and Drug Sensitivity of Extended Spectrum Beta Lactamase (ESBL) Uropathogens*. Journal of Rawalpindi Medical Collage (JRMC). Vol. 19: pp. 155-158.
- Akova, M. 2008. *Sulbactam Containing B-Lactamase Inhibitor Combinations*. Journal Compilation European Society of Clinical Microbiology and Infectious Diseases. Vol. 14: pp. 185-188.
- Alizade, H., Fallah, F., Ghanbarpour, R., Aflatoonian, M. R., Goudarzi, H., and Sharifi, H. 2015. February. *Phylogenetic groups, extended spectrum B-lactamase and metallo-B-lactamase in Escherichia coli isolated from fecal samples of patients with diarrhea in Iran*. Research Institute for Gastroenterology and Liver Disease. Vol. 8: pp. 207-214.
- Bamford, C., Bonorchis , K., Ryan, A., Hoffmann, R., Preneshni, N., Maloba, M., Nana, T., Zietsman, I and Govind, C. 2012. Antimicrobial Susceptibility Patterns of Escherichia coli Strains Isolated from Urine Samples in South Africa from 2007-2011. Southern African Journal of Epidemiology and Infection. Vol. 27. pp: 46-52.
- Banerjee, R., Strahilevitz, J., Johnson, J. R., Nagwekar, P. P., Schora, D. M., Shevrin, I., Du, H., Peterson, L. R and Robiscek, A. 2013. September. *Predictor Molecular Epidemiology of Community Onset Extended Spectrum B-Lactamase Producing Escherichia coli Infection in a Midwestern Community*. Infection Control and Hospital Epidemiology. Vol. 34: pp. 947-953.
- Bano, J. R., Alcalá, J. C., Cisneros, J. M., Grill, F., Oliver, A., Horcajada, J.P., Tortola, T., Mirelis, B., Navarro, G., Cuenca, M., Esteve, M., Pena, C., Llanos, A. C., Canton, R and Pascual, A. 2008. *Community Infection Caused by Extended Spectrum B- Lactamase Producing Escherichia coli*. American Medical Association. Vol. 168: pp. 1897-1902.
- Bano, J. R., Picon, E., Gijon, P., Hernandez, J. R., Ruiz, M., Pena, C., Almela, M., Almirante, B., Grill, F., Colomina, J., Gimenez, M., Oliver, A., Horcajada, J. P., Navarro, G., Coloma, A and Pascual, A. 2010. *Community Onset Bacteremia Due to Extended Spectrum B-Lactamase Producing Escherichia coli : Risk Factors and Prognosis*. Clinical Infectious Disease. Vol. 50: pp. 40-48.
- Baran, I and Aksu, N. 2016. *Phenotypic and Genotypic Characteristics of Carbapenem-Resistant Enterobacteriaceae in a Tertiary-Level Reference*

- Hospital in Turkey*. Baran and Aksu Annual Clinical Microbiology Antimicrobial. Vol. 15: pp. 1-11.
- Bartolini, A., Frasson, I., Cavallaro, A., Richter, S. N and Palù, G. 2014. *Comparison of Phenotypic Methods for the Detection of Carbapenem Non-Susceptible Enterobacteriaceae*. Gut Pathogens. Vol. 6: pp. 1-7.
- Baylis, C. L., Penn, C. W., Thielman, N. M., Guerrant, R. L., Jenkins, C and Gillespie, S. H. 2006. *Escherichia coli and Shigella spp.* in Gillespie, S. H and Hawkey, P. M. *Principles and Practice of Clinical Bacteriology*. 2nd ed., pp. 347-365. England: John Wiley & Sons, Ltd.
- Beceiro, A., Tomas, M and Bou, G. 2013. April. *Antimicrobial Resistance and Virulence: a Successful or Deleterious Association in the Bacterial World?* Clinical Microbiology Review. Vol. 26: pp. 185-230.
- Burman, L. G., Park, J. T., Lindstrom, E. B and Boman, H. G. 1973. October. *Resistance of Escherichia coli to Penicillins: Identification of the Structural Gene for the Chromosomal Penicillinase*. Journal of Bacteriology. Vol. 116: pp. 123-130.
- Bush, K and Jacoby, G. A. 2010. March. *Mini Review : Updated Functional Classification of B-Lactamases*. Antimicrobial Agents and Chemotherapy. Vol. 54: pp. 969-976.
- Chakraborty, D., Saikat, B and Das, S. 2010. *A Study on Infectious Caused by Metallo Beta Lactamase Producing Gram Negative Bacteria in Intensive Care Unit Patients*. American Journal of Infectious Diseases. Vol. 6: pp. 34-39.
- Chaudhary, U and Agarwal, R. 2004. Extended Spectrum  $\beta$  - Lactamases (ESBLs): an Emerging Threat to Clinical Therapeutics. Indian Journal Medical Microbiology. Vol. 22. pp: 75-80.
- Chaudhuri, R. R and Henderson, I. R. 2012. January. *The Evolution of the Escherichia coli Phylogeny*. Elsevier. vol. 12: pp. 214-226.
- Cho, S. Y., Choi, S. M., Park, S. H., Lee, D. G., Choi, J. H and Yoo, J. H. 2016. *Amikacin Therapy for Urinary Tract Infections Caused by Extended Spectrum B-Lactamase Producing Escherichia coli*. Korean Journal Internal Medicine. Vol. 31: pp. 156-161.
- Clermont, O., Bonacorsi, S and Bingen, E. 2000. October. *Rapid and Simple Determination of the Escherichia coli Phylogenetic Group*. American Society for Microbiology. Vol. 66: pp. 4555-4558.
- Clermont, O., Christenson, J. K., Denamur, E and Gordon, D. M. 2013, October. *The Clermont Escherichia coli Phylo-typing Method Revisited :*

- Improvement of Specificity and Detection of New Phylo-groups.* Environmental Microbiology Report. Vol. 5: pp. 58-65.
- Clinical and Laboratory Standards Institute. 2019. *M100 Performance Standards for Antimicrobial Susceptibility Testing.* 29<sup>th</sup> ed.
- Doddaiah, V and Anjaneya, D. 2014. April. *Prevalence of ESBL, AmpC and Carbapenemase Among Gram Negative Bacilli Isolated from Clinical Specimens.* American Journal of Life Sciences. Vol. 2: pp. 76-81.
- Doern, G. V. 2011. *Antimicrobial Susceptibility Testing.* Journal of Clinical Microbiology Vol. 49: pp. S4.
- Falagas, M. E., Kastoris, A. C., Kapaskelis, A. M and Karageorgopoulos, D. E. 2010. *Fosfomycin for the Treatment of Multidrug Resistant, Including Extended Spectrum B-Lactamase Producing, Enterobacteriaceae Infections: a Systemic Review.* Lancet Infectious Disease Vol.10: pp. 43-50.
- Fan, N. C., Chen, H. H., Chen, C. L., Ou, L. S., Lin, T. Y., Tsai, M. H and Chiu, C. H. 2013. May. *Rise of Community Onset Urinary Tract Infection Caused by Extended Spectrum B-Lactamase Producing Escherichia coli in Children.* Elsevier. Vol. 47: pp. 399-405.
- Fernandez, C. L., Dorado, J. S., Barriga, A., Alconero, L. L., Palacios, Z., Hernandez, I. L., Merino, V., Camean, M., Pascual, A., Bano, J. R and the FOREST Study Group. 2015. January. *Fosfomycin Versus Meropenem in Bacteraemic Urinary Tract Infections Caused by Extended Spectrum B-Lactamase Producing Escherichia coli (FOREST): Study Protocol for an Investigator-Driven Randomised Controlled Trial.* BMJ Open. Vol. 5.
- Finch, R. G., Greenwood, D., Norrby, S. R and Whitley, R. J. 2010. *Antibiotic and Chemotherapy Anti Infevtive Agents and Their Use in Therapy.* 9th ed. Toronto: Saunders Elsevier.
- Grennberg, K. G., Boman, H. G., Janson, J. A and Thoren S. 1965. July. *Resistance of Escherichia coli to Penicillins.* Journal of Bacteriology. Vol. 99: pp. 54-62.
- Herzer, J. P., Inouye, S., Inouye, M and Whittam, T. S. 1990. November. *Phylogenetic Distribution of Branched RNA-Linked Multicopy Single-Stranded DNA among Natural Isolates of Escherichia coli.* Journal of Bacteriology. Vol. 172: pp. 6175-6181.
- Johnson, J. R., Delavari, P., Kuskowski, M and Stell, A. L. 2001. *Phylogenetic Distribution of Extraintestinal Virulance-Associated Traits in Escherichia coli.* The Journal of Infectious Disease. Vol. 183: pp. 78-88.

- Jorgensen, J. H and Ferraro, M. J. 2009. *Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary Practices*. Clinical Infectious Diseases. Vol. 49: pp. 1749-1755.
- Kaper, J. B., Nataro, J. P and Mobley, H. L. 2004. *Pathogenic Escherichia coli*. Nature Review. Vol. 2.
- Kazemnia, A., Malahat, M and Dilmaghani, M. 2014. October. *Antibiotic Resistance Pattern of Different Escherichia coli Phylogenetic Groups Isolated from Human Urinary Tract Infection and Avian Colibacillosis*. Iranian Biomedical Journal. Vol. 18: pp. 219-224.
- Kibret, M and Abera, B. 2011. August. *Antimicrobial Susceptibility Patterns of E. coli from Clinical Sources in Northeast Ethiopia*. Africa Health Science. Vol. 11: pp. 40-45.
- Kumar, D., Singh A. K., Ali, M. R and Chander, Y. 2014. January. *Antimicrobial Susceptibility Profile of Extended Spectrum B-Lactamase (ESBL) Producing Escherichia coli from Various Clinical Samples*. Libertas Academia Freedom to Research. Vol. 7: pp. 1-8.
- Kuntaman, K., Santoso, S., Wahjono, H., Mertaniasih, N. M., Lestari, E. S., Farida, H., Hapsari, R., Firmanti, S. C., Noorhamdani, A. S., Santosaningsih, D., Purwono, P. B and Kusumaningrum, D. 2011. December. *The Sensitivity Pattern of Extended Beta Lactamase-Producing Bacteria Against Six Antibiotics that Routinely Used in Clinical Setting*. Journal Indonesia Medical Association. Vol. 61: pp. 482-486.
- Lara, B. M Flaviane., Nery, D. R., Oliveira, P. M., Araujo, L. M., Carvalho, F. R., Messias-Silva, L. C., Ferreira, L. B., Junior, C. F and Pereira, A. L. 2017. February. *Virulence Marker and Phylogenetic Analysis of Escherichia coli Strains with Hybrid EAEC/UPEC Genotypes Recovered from Sporadic Cases of Extraintestinal Infections*. Frontiers in Microbiology. Vol. 8.
- Leber, L. Amy., 2016. *Handbook, Clinical Microbiology Procedures* 4th ed., Vol. 1-3. Washington, DC: American Society for Microbiology.
- Leboffe, M. J and Pierce, B. E. 2011. *A Photographic Atlas for the Microbiology Laboratory* 4th ed. United States of America: Morton Publishing Company.
- Mahon, C. R., Lehman, D. C and Manuselis, G. 2015. *Textbook of Diagnostic Microbiology*. 5th ed. Missouri. pp. 424.
- Manninen, R., Auvinen, H., Huovinen, P and Finnish Study Group for Antimicrobial Resistance (FiRe). 1997. April. *Resistance to Second and Third Generation Cephalosporins among Escherichia coli and Klebsiella Species is Rare in Finland*. Vol. 3: pp. 408-413.

- Murray, P. R., Rosenthal, K. S and Pfaller, M. A. 2013. *Medical Microbiology*. 7th ed. Philadelphia: Elsevier Saunders.
- Park, Y. S., Haduch, J. M., Shutt, K. A., Yarabinec, D. M., Johnson, L. E., Hingwe, A., Lewis, J. S., Jorgensen, J. H and Doi, Y. 2012. January. *Clinical and Microbiologic Characteristics of Cephalosporin-Resistant Escherichia coli at Three Centers in the United States*. Antimicrobial Agent and Chemotherapy. Vol. 56: pp. 1870-1876.
- Paterson, D. L. 2000. May. *Recommendation for Treatment of Severe Infection Caused by Enterobacteriaceae Producing Extended Spectrum  $\beta$  - Lactamases (ESBLs)*. Clinical Microbiology Infection. Vol. 6. pp: 460-463.
- Picard, B., Garcia, J. S., Gouriou, S., Duriez, P., Brahimi, N., Bingen, E., Elion J., and Denamur, E. 1999. Februari. *The Link between Phylogeny and Virulence in Escherichia coli Extraintestinal Infection*. American Society for Microbiology. Vol. 67: pp. 546-553.
- Pitout, J. D and Laupland, K. B. 2008. March. *Extended Spectrum  $\beta$  - Lactamase Producing Enterobacteriaceae: an Emerging Public Health Concern*. Lancet Infection Disease. Vol. 8. pp: 159-166.
- Poirel, L., Madec, J. I., Lupo, A., Schink, A. K., Kieffer, N., Nordmann, P and Schwarz, S. 2018. July. *Antimicrobial Resistance in Escherichia coli*. Microbiology Spectrum.
- Procop, Q. W., Church, D. L., Hall, G. S., Janda, W. M., Koneman, E. W., Schreckenberger, P. C and Woods. 2017. *Koneman's Color Atlas and Textbook of Diagnostic Microbiology 7<sup>th</sup> ed.* pp. 235-258.
- Rajabnia, M., Forghani, M. S., Hasani, S., Bahadoram, M., Mohammadi, M and Barahman, M. 2019. July. *Prevalence and Antibiotic Resistance Pattern of Extended Spectrum Beta Lactamase Producing Escherichia coli Isolated from Urinary Tract Infection*. Journal of Renal Injury Prevention. Vol. 8: pp. 78-81.
- Roshene, R., Gopinath, P and Jayalakshmi. 2015. *Antibiotic Sensitivity Pattern and ESBL Detection among Clinical Isolates of Escherichia coli*. Journal of Pharmaceutical Sciences and Research. Vol. 7: pp. 878-881.
- Russo, T. A., Johnson, J. R. 2000. May. *Proposal for a New Inclusive Designation for Extraintestinal Pathogenic Isolates of Escherichia coli : ExPEC*. The Journal of Infectious Diseases. Vol. 181: pp. 1753-1754.
- Ryke, C. A., Banevicius M. A., Fan, H. W and Nicolau, D. P. 2007. April. *Bactericidal Activities of Meropenem and Ertapenem Against Extended Spectrum B-Lactamase Producing Escherichia coli and Klebsiella*

- pneumoniae in a Neutropenic Mouse Thigh Model*. Antimicrobial Agents and Chemotherapy Vol. 51: pp. 1481-1486.
- Shaikh, S., Fatima, J., Shakil, S., Rizvi, S. M and Kamal, M. A. 2014. August. *Antibiotic Resistance and Extended Spectrum Beta-Lactamase: Types, Epidemiology and Treatment*. Saudi Journal of Biological Sciences.
- Singh, R. E., Raghukumar, K. G., Veena, M., Vishwanath, G., Rao, P. N and Murlimanju, B. V. 2012. March. *ESBL Production: Resistance Pattern in Escherichia coli and Klebsiella pneumoniae, a Study by NCCLS Method*. Research Journal of Pharmaceutical, Biological and Chemical Science. Vol. 3: pp. 559-565.
- Souza, V., Rocha, M., Valera, A and Eguiarte, L. E. 1999. August. *Genetic Structure of Natural Populations of Escherichia coli in Wild Host on Different Continents*. American Society for Microbiology. Vol. 65: pp. 3373-3385.
- Watkins R and Bonomo R. A.  *$\beta$ -Lactam Antibiotics in Anti Infective Therapy*. pp. 1203-1216.
- Zurfluh, K., Abgottspon, H., Hachler, H., Nuesch-Inderbinen, M and Stephan, R. 2014. April. *Quinolone Resistance Mechanisms among Extended Spectrum Beta-Lactamase (ESBL) Producing Escherichia coli Isolated from Rivers and Lakes in Switzerland*. Plos One. Vol. 9.